The genetic background in which a disease-associated mutation is expressed can have a profound impact on the resulting disease phenotype. The identification of so-called ‘modifier genes’ can therefore provide insights into disease pathophysiology and could also reveal novel targets for therapeutic intervention. In this study, Joseph Buxbaum and colleagues sought to determine whether modifier loci affect the severity and range of autistic behaviours and developmental deficits associated with the genetic disorder Phelan-McDermid syndrome (PMS). Deletion of SHANK3, a gene that has been strongly linked to autism spectrum disorders, is known to be a major cause of the neurobehavioural manifestations of PMS. Buxbaum and co-authors assessed the effects of Shank3 deficiency in three different strains of laboratory mice. Their extensive behavioural tests demonstrate that phenotypes observed in Shank3-deficient mice are largely similar regardless of strain. This indicates that differences in genetic background are unlikely to account for the high variability in disease phenotypes observed in individuals with PMS. This unexpected finding suggests that modifier loci do not play a role in PMS pathogenesis, and other potential contributory factors should be explored to gain a deeper understanding of the underlying disease mechanisms. Page 667
Evidence that modifier loci have no effect on phenotypic severity in SHANK3-linked autism
Evidence that modifier loci have no effect on phenotypic severity in SHANK3-linked autism. Dis Model Mech 1 June 2014; 7 (6): e603. doi:
Download citation file:
Advertisement
Cited by
New Special Issue: Translating Multiscale Research in Rare Disease. Edited by Monica Justice, Monkol Lek, Karen Liu and Kate Rauen.
This special issue features original Research, Resources & Methods and Review-type articles that aim to interrogate the mechanisms of rare diseases to foster meaningful clinical progress in their diagnosis and treatment.
The role of the International Society for Stem Cell Research (ISSCR) guidelines in disease modelling
The ISSCR provides comprehensive guidelines and standards for using human stem cells in biomedical research. In this Editorial, Cody Juguilon and Joseph Wu discuss how and why these should be incorporated in disease modelling research.
Subject collection: Building advocacy into research
DMM’s series - Building advocacy into research - features interviews, ‘The Patient’s Voice’, with patients and advocates for a range of disease types, with the aim of supporting the highest quality research for the benefit of all patients affected by disease.
Read & Publish Open Access publishing: what authors say
We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Biologists @ 100 - join us in Liverpool in March 2025
We are excited to invite you to a unique scientific conference, celebrating the 100-year anniversary of The Company of Biologists, and bringing together our different communities. The conference will incorporate the Spring Meetings of the BSCB and the BSDB, the JEB Symposium Sensory Perception in a Changing World and a DMM programme on antimicrobial resistance. Find out more and register your interest to join us in March 2025 in Liverpool, UK.
Other journals from
The Company of Biologists